Tango Therapeutics’ $50 Million Equity Financing

Goodwin Procter LLP advised Tango Therapeutics on the deal.

Tango Therapeutics announced the closing of $50 million in equity financing.The financing was led by Casdin Capital and included existing investors Boxer Capital of the Tavistock Group and Cormorant Asset Management as well as new investor Gilead Sciences. The company will use the funding to initiate clinical studies of its lead program in the next 18 months and drive progress for other wholly owned programs in late-stage drug discovery.

Tango is a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies. The company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.

The Goodwin team was led by Gabriela Morales-Rivera and Bill Collins (Picture) and included Mitchell Bloom and Katie Hand.

Involved fees earner: Mitchell Bloom – Goodwin Procter; William Collins – Goodwin Procter; Katherine Hand – Goodwin Procter; Gabriela Morales-Rivera – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Tango Therapeutics Inc;

Author: Ambrogio Visconti